Otilimab ELISA Kit

Otilimab is an IgG1 mAb that binds to GM-CSF and hinders its interaction with GM-CSFRα; it was developed by Morphosys AG (MOR-103) and then sublicensed to GSK (GSK3196165) to conduct large-scale clinical trials.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.